The PARP inhibitor AZD2281 (Olaparib) induces autophagy/mitophagy in BRCA1 and BRCA2 mutant breast cancer cells
Banu Arun(The University of Texas Health Science Center at Houston), Bülent Özpolat(The University of Texas MD Anderson Cancer Center)
Cited by 114
Related Papers
Association of Type and Location of<i>BRCA1</i>and<i>BRCA2</i>Mutations With Risk of Breast and Ovarian Cancer
|JAMA|2015|507
NCCN Guidelines® Insights: Genetic/Familial High-Risk Assessment: Breast, Ovarian, and Pancreatic, Version 2.2024
|Journal of the National Comprehensive Cancer Network|2023|284
Regulation of autophagy by polyphenolic compounds as a potential therapeutic strategy for cancer
|Cell Death and Disease|2014|257
Clinical practice guidelines for BRCA1 and BRCA2 genetic testing
|European Journal of Cancer|2021|174
Polygenic risk scores and breast and epithelial ovarian cancer risks for carriers of BRCA1 and BRCA2 pathogenic variants
|Genetics in Medicine|2020|145